EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials

Peter J Goadsby iD, Tim P Jürgens iD, Elimor Brand-Schieber iD, Krisztian Nagy iD, Yingyi Liu iD, Ramesh Boinpally iD, Sven Stodtmann iD, Joel M Trugman iD

Cephalalgia · 2025

DOI: 10.1177/03331024251320610 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cephalalgia, 2025. Verfasst von Peter J Goadsby und 7 weiteren Autor:innen. Beteiligte Einrichtung: NIHR-King's Clinical Research Facility, King's College, London, UK. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide Receptor Antagonists, Migraine Disorders, Pyridines, Pyrroles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Published evidence supporting efficacy of calcitonin gene-related peptide receptor antagonists as acute migraine treatments in males is limited.

Methods

To fill the gap, we present male and female data from four ubrogepant and four atogepant randomized, double-blind, placebo-controlled trials for acute and preventive treatment of migraine, respectively. Acute outcomes included 2-h pain freedom and absence of most bothersome symptom (co-primary; headache-phase randomized, double-blind, placebo-controlled trials); absence of moderate-to-severe headache within 24 h (primary; prodrome randomized, double-blind, placebo-controlled trial). Preventive outcome included change from baseline in mean monthly migraine days across 12 weeks (primary).

Results

Pooled data from phase 3 headache-phase ubrogepant randomized, double-blind, placebo-controlled trials showed similar rates of pain freedom (19.4% vs 21.1%) and absence of most bothersome symptom (35.1% vs 39.0%) 2 h post-dose between males and females, respectively. Time course of pain freedom and absence of most bothersome symptom over 48 h was similar between male and female subgroups. Comparable reductions in mean monthly migraine days across 12-week treatment periods were found between males and females treated with atogepant 60 mg once-daily in pooled episodic migraine and chronic migraine randomized, double-blind, placebo-controlled trials. Conclusion/Interpretation In ubrogepant and atogepant randomized, double-blind, placebo-controlled trials, although analysis power for males is limited due to small sample sizes, evidence supports similar treatment effects in males and females with migraine.

Trial registration

ClinicalTrials.gov: NCT02828020; NCT02867709; NCT04492020; NCT01613248; NCT02848326; NCT03777059; NCT04740827; NCT03855137

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcitonin Gene-Related Peptide Receptor AntagonistsMigraine DisordersPyridinesPyrrolesAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodRandomized Controlled Trials as TopicTreatment OutcomeClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

Episodic migrainecalcitonin gene–related peptidechronic migrainegepantssexual dimorphism

Substanzen

Calcitonin Gene-Related Peptide Receptor AntagonistsPyridinesPyrrolesubrogepant

Autor:innen und Institutionen

  • NIHR-King's Clinical Research Facility, King's College, London, UK.
  • Department of Neurology, University of California, Los Angeles, CA, USA.
  • Headache Centre North-East, Department of Neurology, University Medical Center Rostock, Rostock, Germany.
  • Department of Neurology, KMG Hospital Güstrow, Güstrow, Germany.
  • AbbVie, North Chicago, IL, USA.
  • AbbVie, Budapest, Hungary.

ORCID-Profile: Peter J Goadsby, Tim P Jürgens, Elimor Brand-Schieber, Krisztian Nagy, Yingyi Liu, Ramesh Boinpally, Sven Stodtmann, Joel M Trugman

Förderung

  • AbbVie

Zitieren

APA

Goadsby, P. J., Jürgens, T. P., Brand-Schieber, E., Nagy, K., Liu, Y., Boinpally, R., Stodtmann, S., & Trugman, J. M. (2025). Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials. Cephalalgia. https://doi.org/10.1177/03331024251320610

Vancouver

Goadsby PJ, Jürgens TP, Brand-Schieber E, Nagy K, Liu Y, Boinpally R, et al. Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials. Cephalalgia. 2025. doi:10.1177/03331024251320610

BibTeX
@article{Goadsby2025,
  author = {Goadsby, Peter J and Jürgens, Tim P and Brand-Schieber, Elimor and Nagy, Krisztian and Liu, Yingyi and Boinpally, Ramesh and Stodtmann, Sven and Trugman, Joel M},
  title = {Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials},
  journal = {Cephalalgia},
  year = {2025},
  doi = {10.1177/03331024251320610}
}
Kostenlos starten →